论文部分内容阅读
目的：探讨葡萄糖酸镁的抗心律失常疗效。方法：１０８例心律失常病人采用随机、单盲对照方法分为葡萄糖酸镁治疗组７１例（男性３１例，女性４０例；年龄５５±ｓ１５ａ）和门冬氨酸钾镁对照组３７例（男性１９例，女性１８例；年龄５７±１３ａ），在原用抗心律失常药物欠佳的情况下，分别加用葡萄糖酸镁和门冬氨酸钾镁各１０ｍＬ，ｐｏ，ｔｉｄ，４ｗｋ。结果：治疗组房性早搏和室性早搏的总有效率分别为６５％及７９％，与对照组的５８％和７２％相似，Ｐ＞０．０５。动态心电图检查显示２药应用后房性早搏和室性早搏数均明显减少。结论：葡萄糖酸镁可作为抗心律失常的辅助药物。
Objective: To investigate the antiarrhythmic effect of magnesium gluconate. Methods: A total of 108 patients with arrhythmia were randomly divided into two groups: 71 patients (31 males, 40 females; age 55 ± s15a) and 37 patients of potassium magnesium aspartate control group (male 19 cases, 18 females; age 57 ± 13a), in the case of the original anti-arrhythmic drugs are poor, respectively, with magnesium gluconate and potassium aspartate 10mL, po, tid, 4wk. Results: The total effective rates of atrial premature beats and ventricular premature beats in the treatment group were 65% and 79%, respectively, which were similar to those in the control group (58% and 72%, P> 0.05). Holter examination showed 2 drug application of atrial premature beats and ventricular premature beats were significantly reduced. Conclusion: Magnesium gluconate can be used as an anti-arrhythmia adjuvant.